Investor Relations

CORPORATE PROFILE
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics utilizes its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Corporate Presentation
Share Price

Minimum 15 minutes delayed. Source: LSEG

Media & IR Contact
Investor Relations & Media Contact

Robin Garner
Investor Relations
Contact Us